JUN 11, 2020 7:34 AM PDT

Glowing Chemical Reactions Could Put an End to Bad COVID Tests

WRITTEN BY: Tara Fernandez

Advancements in diagnostic technologies are paving the way for the next generation of ultra-sensitive serological tests — capable of making routine blood tests faster, cheaper, and more accurate than ever before. A collaborative study between researchers at the University of Bologna, together with industry partners Roche and Hitachi, was recently published in Nature Communications, demonstrating the potential of this breakthrough.

Serological diagnostics work by detecting the presence of specific molecules, known as biomarkers, within a patient’s blood sample. Many immunoassays for COVID-19, for instance, indicate that an individual is infected by picking up antibodies against SARS-CoV-2 and, through a series of chemical reactions, create a quantifiable signal. 

One such chemical reaction is a light-emitting mechanism called electrochemiluminescence, or ECL. ECL-based tests are excellent diagnostics as they generally have long shelf lives, can be read in under 20 minutes, and require only tiny volumes of a patient’s blood sample.

Though commonly used, these tests can sometimes fall short in terms of reliability; biomarkers need to reach a certain threshold concentration before they are detectable. The latest developments promise to change that, boosting the sensitivity of ECL-based serological tests by up to 128 percent. This means fewer false negatives and disease being caught at much earlier stages — the weakest link in many currently-available COVID tests.

To achieve this, the team identified a series of novel reactants and imaging techniques to amplify ECL signals and make ECL-based serological tests more efficient. Diagnostic biomarkers would not be limited to measuring levels of antibodies but would also encompass enzymes, proteins, peptides, and hormones, all of which could point to the presence of disease.

Lead researcher at the University of Bologna, Giovanni Valenti commented on the implications of this work, saying, "Our work represents something unprecedented in the field of ECL because it relies on the enhancement of the signal as opposed to the enhancement of the target as it usually happens with enzymatic methods or PCR (Polymerase Chain Reaction)."

"These results pave the way for the development of ultra-sensitive serological tests," Valenti added. 

 

Sources: Technology Networks, Nature Communications


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 13, 2020
Cancer
Workers in Transportation Might be More at Risk for Cancer
JUL 13, 2020
Workers in Transportation Might be More at Risk for Cancer
Road transportation workers are essential employees in any country. They represent truck, bus, taxi, and other such driv ...
JUL 16, 2020
Cell & Molecular Biology
Newly Discovered Cell Type Predicts Arthritis Flares
JUL 16, 2020
Newly Discovered Cell Type Predicts Arthritis Flares
Arthritis can be a very unpredictable disease, causing challenges for those that have it by suddenly flaring up and maki ...
JUL 24, 2020
Immunology
Telling the Difference Between Eczema and Psoriasis
JUL 24, 2020
Telling the Difference Between Eczema and Psoriasis
It can be extremely different even for professionals to tell the difference between psoriasis, an autoimmune disorder, a ...
AUG 05, 2020
Cancer
A New Test to Analyze Cell-Free DNA in Cancer Diagnostics
AUG 05, 2020
A New Test to Analyze Cell-Free DNA in Cancer Diagnostics
Cell-free DNA (cfDNA) are small pieces of genomic DNA that have escaped into the bloodstream either through active relea ...
SEP 02, 2020
Cancer
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
SEP 02, 2020
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse ...
SEP 12, 2020
Cardiology
Is Hyperuricemia an Indicator of Aortic Disease?
SEP 12, 2020
Is Hyperuricemia an Indicator of Aortic Disease?
Living in a culture of excess can have its benefits, but also its drawbacks. Diabetes is a common disease that is gettin ...
Loading Comments...